Survival outcomes of beta-blocker usage in HER2-positive advanced breast cancer patients: a retrospective cohort study.
Ther Adv Drug Saf
; 14: 20420986231181338, 2023.
Article
in En
| MEDLINE
| ID: mdl-37359444
Use of beta-blockers for cancer therapy Summary: Background ⢠Evidence from preclinical research suggests that beta-blockers (BBs) could serve as anticancer agents and immune boosters. ⢠Beta-blockers could therefore be a potential therapy for cancers. ⢠Trastuzumab is a drug that affects the overall survival (OS) and progression-free survival (PFS) of patients with HER2-positive breast cancer by binding to the extracellular domain of HER2. ⢠This study investigates the effect of BBs on trastuzumab therapy in patients with advanced breast cancer. Method ⢠This retrospective study was conducted between January 2012 and May 2021. ⢠Patients with HER2-positive advanced breast cancer who were treated using trastuzumab monotherapy or trastuzumab concomitantly with any dose of a BB were recruited and divided into three groups. ⢠One group received only the trastuzumab (BB−/trastuzumab+), another group received both BB+ (non-selective) and trastuzumab [BB+ (non-selective)/trastuzumab+], and the third group received both BB+ (selective) and trastuzumab [BB+ (selective)/trastuzumab+]. ⢠The PFS and OS were determined and compared between the treatment groups. Results ⢠We enrolled 221 patients (mean age: 56.1 ± 11.1 years) in the study. ⢠The estimated median PFS and OS were significantly lower in the BB+ (non-selective)/trastuzumab+ and BB+ (selective)/trastuzumab+ groups than in the BB−/trastuzumab+ group. ⢠The use of BBs was associated with worse PFS and OS in patients with HER2-positive advanced breast cancer. Conclusion ⢠Trastuzumab treatment was independently associated with poorer PFS and OS for patients who used BB prior to initiating trastuzumab therapy for advanced HER2-positive breast cancer. ⢠BB use potentially has a negative effect on patients with HER2-positive advanced breast cancer. ⢠Future studies with larger sample sizes are needed to validate our findings.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Language:
En
Journal:
Ther Adv Drug Saf
Year:
2023
Document type:
Article
Country of publication:
United kingdom